KJ-101

N/A

Report date: 2025/02/13 14:24:00

Base Information

Drug NameKJ-101

Drug Alias NameKJ-101

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody

Mechanisms of ActionAnti-Cluster of differentiation 47Anti-PD-1Dopamine D2 receptor antagonists

TargetsCluster of differentiation 47Programmed cell death protein 1Dopamine D2 receptor

Therapy Area/IndicationsCarcinoma, Neuroendocrine

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesKisoji Biotechnology Inc

China Registration ClassN/A

Develop Information

Active CompaniesKisoji Biotechnology Inc

Inactive CompaniesN/A

Active IndicationsCarcinoma, Neuroendocrine

Inactive IndicationsN/A

Other Information

ATC CodeN/A